Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) saw a significant drop in short interest in the month of July. As of July 31st, there was short interest totalling 578,200 shares, a drop of 7.5% from the July 15th total of 625,300 shares. Based on an average daily volume of 160,900 shares, the short-interest ratio is presently 3.6 days. Currently, 3.8% of the shares of the stock are sold short.
Immix Biopharma Stock Performance
NASDAQ IMMX opened at $2.17 on Wednesday. The stock’s fifty day moving average is $2.10 and its two-hundred day moving average is $2.47. The firm has a market capitalization of $57.32 million, a P/E ratio of -2.33 and a beta of 0.17. Immix Biopharma has a fifty-two week low of $1.75 and a fifty-two week high of $7.75.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.06. As a group, sell-side analysts forecast that Immix Biopharma will post -0.88 EPS for the current year.
Institutional Investors Weigh In On Immix Biopharma
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Immix Biopharma in a research note on Monday.
Check Out Our Latest Report on Immix Biopharma
About Immix Biopharma
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Featured Articles
- Five stocks we like better than Immix Biopharma
- Comparing and Trading High PE Ratio Stocks
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- How Investors Can Find the Best Cheap Dividend Stocks
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Dividend Capture Strategy: What You Need to Know
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.